Clover Health Investments, Corp. (CLOV)
A Clover Health Director Sold Over 67,000 Company Shares. Here's a Closer Look at the Transaction.
Director Carladenise Edwards sold 67,160 shares for a transaction value of approximately ~$230,000 on May 18, 2026, at a weighted average price of around $3.42 per share. This sale represented 19% of her direct holdings at the time, reducing direct ownership from 352,592 to 285,432 shares.
Clover Health Investments, Corp. (CLOV) Q1 2026 Earnings Call Transcript
Clover Health Investments, Corp. (CLOV) Q1 2026 Earnings Call Transcript
Clover Health Investments, Corp. (CLOV) Meets Q1 Earnings Estimates
Clover Health Investments, Corp. (CLOV) came out with quarterly earnings of $0.07 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.05 per share a year ago.
Here's Why You Should Retain Clover Stock in Your Portfolio for Now
CLOV rides strong membership growth and an AI-driven care model, but rising costs and policy risks cloud the near-term outlook.
Clover Health: Strong Growth, Improving Margins, And A Mispriced Stock
Clover Health is positioned for a major turnaround, with operations and profitability metrics improving sharply despite market skepticism. CLOV projects 46% membership growth and 49% revenue growth for 2026, guiding toward its first full year of positive GAAP net income. Operating leverage is materializing as SG&A improves, member retention exceeds 95%, and mature cohorts deliver over $200 monthly profit per member.
Here's Why You Should Retain Clover Stock in Your Portfolio for Now
CLOV rides 38% Medicare Advantage growth and rising EBITDA, but higher medical costs and policy risks cloud its near-term margin outlook.
Clover Health Q4 Earnings Meet Estimates, Sales Beat, Membership Rises
CLOV Q4 loss matches estimates. Revenues jump 45%.
Clover Health Investments, Corp. (CLOV) Q4 2025 Earnings Call Transcript
Clover Health Investments, Corp. (CLOV) Q4 2025 Earnings Call Transcript
Clover Health Is Undervalued With Clear Signs Of A 2026 Profit Breakout
Clover Health Investments is now a contrarian buy, with the market underestimating its path to profitability in 2026. CLOV's member retention exceeds 90%, older cohorts generate $217 monthly profit, and the Clover Assistant AI is driving clinical and financial improvements. The stock trades at less than 0.5x 2026 sales, with a fair value estimate of $3.30 per share—28% above current levels.
Here's Why You Should Retain CLOV Stock in Your Portfolio for Now
Clover Health shows strong membership growth, rising revenues and sustained EBITDA gains from Clover Assistant, though near-term margin pressure remains a risk.
Clover Health Investments, Corp. (CLOV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Clover Health Investments, Corp. (CLOV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CLOV Reports MA Membership Growth, Signals GAAP Profitability in 2026
Clover Health posts 53% AEP PPO membership growth, lifts total members to 153,000, and says the momentum positions it for GAAP net income profitability in 2026.
